Statins spending: -17%
Statins usage: +1%
Access was widened for primary arterial hypertension (PAH) treatments, and we made it easier for clinicians to apply for funding.
We removed the requirement for a panel application from some PAH treatments and allowed earlier initiation, quicker access to dual therapy and the addition of triple therapy for some patients.
We also made epoprostenol available in the community, and started funding rivaroxaban, without restriction.
Rivaroxaban is an oral anti-coagulant, generally used for the prevention of stroke and other thromboembolic events. It provides an additional option for those patients unable to take the currently funded treatments.
Last updated: 13 December 2018